![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Cholelithiasis (gallstones) among patients exposed to atazanavir, other PIs, and PI-free regimens
|
|
|
Reported by Jules Levin
ICAAC 2014 Sept 5-9 Wash DC
Ella Nkhoma, PhD1, Monica Kumar, MD2, Patricia Hines, BA3, Vidya Moorthy, MS4 1Global Pharmacovigilance and Epidemiology (GPVE), Bristol-Myers Squibb (BMS), Wallingford, CT, USA; 2GPVE, BMS, Hopewell, NJ, USA; 3Center for Observational Research and Data Sciences, BMS, Hopewell, NJ, USA; 4Mu Sigma, Northbrook, Illinois, Chicago, USA
![HCV1.gif](../images/090914/090914-3/HCV1.gif)
![HCV2.gif](../images/090914/090914-3/HCV2.gif)
![HCV3.gif](../images/090914/090914-3/HCV3.gif)
![HCV4.gif](../images/090914/090914-3/HCV4.gif)
![HCV5.gif](../images/090914/090914-3/HCV5.gif)
![HCV6.gif](../images/090914/090914-3/HCV6.gif)
![HCV7.gif](../images/090914/090914-3/HCV7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|